Adjuvant Systemic Treatment for Renal Cancer After Surgery: A Network Meta-Analysis
BackgroundApproximately 15% to 20% of patients will experience disease recurrence following surgical removal of renal cell carcinoma. A range of pharmacological agents is prescribed for metastatic renal cell carcinoma, but there are trials testing whether these have an earlier role in the adjuvant s...
Main Authors: | Niranjan J. Sathianathen, Marc A. Furrer, Christopher J. Weight, Declan G. Murphy, Shilpa Gupta, Nathan Lawrentschuk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Société Internationale d’Urologie Journal |
Subjects: | |
Online Access: | https://siuj.org/index.php/siuj/article/view/206/148 |
Similar Items
-
Complications of Outpatient and Inpatient Renal Biopsy: A Systematic Review and Meta-Analysis
by: Shih-Yi Lin, et al.
Published: (2021-04-01) -
Systemic adjuvant therapies in renal cell carcinoma
by: Sebastiano Buti, et al.
Published: (2012-10-01) -
Primary renal leiomyosarcoma in adult patients: a systematic review and individual patient data analysis
by: Kannan Periasamy, et al.
Published: (2024-03-01) -
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
by: Ray Manneh, et al.
Published: (2022-03-01) -
Clinical effect of rhubarb on the treatment of chronic renal failure: A meta-analysis
by: Wei Huang, et al.
Published: (2023-04-01)